BioCryst's third quarter swings to higher profit while year-to-date parent lines flip to a loss

Bottom line

For the three-month reporting period covered by this Quarterly Report on Form 10-Q filed by BIOCRYST PHARMACEUTICALS INC (BCRX), diluted earnings per share of $0.3 per diluted share USD/SHARES represent a year-over-year increase from the prior-year comparative of $0.02 per diluted share USD/SHARES, with both periods remaining profitable. Net Income (Loss) Attributable to Parent for the quarter rose to $78,395,000 USD from $5,085,000 USD, and Operating Income (Loss) for the quarter moved higher to $98,465,000 USD versus $29,786,000 USD, holding a profit-to-profit transition in each line.

The six-month year-to-date picture tells a different story. Diluted earnings per share swung from a profit of $0.02 per diluted share USD/SHARES in the prior-year comparative to a loss of -$2.59 per diluted share USD/SHARES for the current the six months ended June 30, 2026 window. Net Income (Loss) Attributable to Parent followed the same profit-to-loss transition, moving from $5,117,000 USD to -$643,417,000 USD, while Operating Income (Loss) shifted from a profit of $51,013,000 USD to a loss of -$603,133,000 USD. Across every line item reviewed in this section, the quarter strengthened year over year while the six-month window weakened, a divergence consistent with the pattern flagged in Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base for a different issuer.

The forward-looking commentary at the front of the report discusses strategic priorities including the implementation and estimated timing of completion of the Birmingham Closure Plan, the strategic shift to prioritize external innovation announced in June of the prior reporting cycle, the launch of the ORLADEYO oral pellet formulation, the transition to a new sole source specialty pharmacy for ORLADEYO shipments, and ongoing collaboration arrangements with Kaken, Neopharmed, Shionogi, and Green Cross. None of those forward-looking items in this section's quoted material directly explains the swing in the the six months ended June 30, 2026 earnings lines reviewed here.

Within this report the the six months ended June 30, 2026 earnings reversal can be described qualitatively only — current-period loss versus prior-period profit — without attribution to any single line item or driver in the source narrative. Operating activities, investing activities, and financing activities cash-flow direction are noted elsewhere in the filing but lie outside this section's scope. The note on significant accounting policies (Note 1) and the condensed consolidated financial statements (Note 14) provide the underlying primary statements but do not single out a cause for the the six months ended June 30, 2026 profit-to-loss move. The note on the acquisition of Astria Therapeutics (Note 2) and the financing obligations note (Note 7) appear in the catalog but are not invoked as causal explanations here.

Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

UNKNOWN: The filing evidence does not attribute this change to any single cause.

Financial performance

- Across the six-month reporting window, BIOCRYST PHARMACEUTICALS INC moved from parent-level profitability to a parent-level loss on every reported earnings line. $51,013,000 for the six months ended June 30, 2025 reversed to an operating loss of -$603,133,000 in the six months ended June 30, 2026, and the corresponding Net Income (Loss) Attributable to Parent followed the same arc, from $5,117,000 to -$643,417,000. 59 per diluted share USD/SHARES in the six months ended June 30, 2026, a profit-to-loss transition on the longer horizon.

- The three-month reporting period tells the opposite story at the parent level. 3 per diluted share USD/SHARES. The quarter therefore stayed profitable on every line while the year-to-date window deteriorated, leaving a six-month result that is worse than the prior year even though the standalone three-month period improved.

- The accounting frame for these results is the set of disclosures in Note 1 (Significant Accounting Policies and Concentrations of Risk), Note 2 (the Astria Therapeutics, Inc. transaction context), Note 7 (Financing Obligations), and the interim-entity note in Note 14. Those four referenced notes describe the policies, the recently acquired subsidiary footprint, the financing-arrangement exposure, and the basis of preparation for the condensed consolidated statements; the cited risk-factor language in Item 1A is the same disclosure from which this analysis is drawn.

- Counter-evidence is anchored in the cash-flow statement rather than in earnings: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. The filing evidence does not attribute this change to any single cause. ; there is no peer or industry comparator inside this filing, so The filing evidence contains no peer or industry comparison..

Management has not, in the cited risk-factor section, named a single driver for the six-month profit-to-loss flip on diluted EPS, Net Income (Loss) Attributable to Parent, or Operating Income (Loss), so the change is recorded without a stated cause. The wider Item 1A discussion does flag capital-raising risk, merger-related risk tied to the Astria deal, pipeline development risk, third-party reliance risk, and Blackstone Loan Agreement covenants as principal risk themes, but the filing does not tie any one of those themes to the specific half-year earnings move.

- For comparison baselines used elsewhere in this analysis, the relevant references are the three months ended June 30, 2025 and the six months ended June 30, 2025 for the prior-year quarter and year-to-date comparatives, the three months ended June 30, 2026 and the six months ended June 30, 2026 for the current reporting periods, and Note 1, Note 2, Note 7, and Note 14 for the accounting context that frames those baselines. Guidance, forward-looking statements, and any forward EPS or revenue outlook are addressed in the management commentary section rather than restated here.

Operating drivers and segments

The Company reports a single operating and reportable segment, as disclosed in the cited segment information note; segment-level breakdowns of revenue mix, cost of sales, or operating expenses are therefore not separately presented within the filing. Operating Income (Loss) for the three-month reporting period was $98,465,000 USD, a profit that compares with the prior-year quarter figure of $29,786,000 USD, also a profit. Operating Income (Loss) for the six-month year-to-date period was -$603,133,000 USD, a loss that compares with the prior-year six-month figure of $51,013,000 USD, a profit. The six-month period therefore moves from profit to loss on this line, while the quarter moves higher on the same line. Because the filing presents one consolidated segment, no sub-segment revenue or margin detail is available to attribute the swing between the quarter and the year-to-date window.

Management frames the period around its commercial lead asset, the ORLADEYO franchise, alongside pipeline assets including navenibart and additional referenced candidates, and around the strategic shift to prioritize external innovation announced earlier in the calendar year. The forward-looking commentary in this Form 10-Q filing also references the implementation and estimated timing of completion of the Birmingham Closure Plan, partner relationships covering ORLADEYO, navenibart, and peramivir in various territories, the Blackstone Loan Agreement covenant posture, and the Merger transaction referenced in the filing. Management discussion of how those strategic actions translated into the swing between a profitable quarter and a loss-making six-month period is not separately quantified within the excerpted evidence. The filing evidence does not attribute this change to any single cause.

Independent analysis of the operating line is constrained by the single-segment presentation. The quarter-over-quarter improvement on Operating Income (Loss) is consistent with the pattern of a profitable three-month period versus the prior-year quarter, while the six-month result moving from a profit to a loss over the longer window suggests that earlier-period results within the year-to-date were weaker than the closing quarter. Counter-evidence from the cash flow lines, drawn from the same filing, points in the opposite direction on a quality-of-earnings basis for the six-month comparison: Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.. Readers comparing operating drivers across companies may also find context in Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base, where a single-segment filer with a divergent six-month profit/loss profile is examined. The filing evidence contains no peer or industry comparison.

Cash flow and capital

Reported facts

- The company ended the period with cash and cash equivalents of $154,972,000, accounts receivable (after the allowance for credit loss) of $110,757,000, accounts payable of $11,459,000, and long-term debt excluding current maturities of $395,400,000, all measured as of the balance sheet date of June 30, 2026. - For the six-month year-to-date period the six months ended June 30, 2026, net cash provided by operating activities was $42,551,000, net cash used in investing activities was -$378,796,000, and net cash provided by financing activities was $401,399,000. - For the prior-year comparative six-month period the six months ended June 30, 2025, net cash provided by operating activities was $13,785,000, net cash provided by investing activities was $56,222,000, and net cash used in financing activities was -$73,157,000.

Management explanations

- Management states that financial resources available at the balance sheet date are expected to fund operations for at least the next twelve months, and that any future capital would likely come from issuing securities such as common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities or units through private placements or registered public offerings, referencing Note 7 for financing obligations and Note 1 for the significant accounting policies and risk concentrations that frame that judgment. - Management further notes that liquidity going forward will largely depend on the success of its products and product candidates, business-development efforts, the timing and scope of research, development and commercial spending, and key regulatory and operational developments.

Analyst inference

- Compared with the prior-year six-month period, net cash provided by operating activities increased, net cash provided by investing activities moved to a use from a source, and net cash from financing activities moved to a source from a use. - The balance sheet at the balance sheet date of June 30, 2026 shows a positive cash and cash equivalents position sitting alongside long-term debt excluding current maturities, while working capital includes accounts receivable and accounts payable as cited above.

Counter-evidence

- Even though operating cash generation strengthened over the six-month window, reported parent-level net income moved from a profit to a loss over the longer reporting window. - Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

Unknowns

- the filing does not allocate cash flow lines between ORLADEYO, RAPIVAB and pipeline activities, nor does it break financing inflows into equity versus debt components for this period. - The filing evidence does not attribute this change to any single cause. - The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison.

Peer and historical context

The reader-facing comparison below uses only the year-over-year relations the filing's authorized comparison ledger permits. No independent peer set is established here, and no external industry benchmark is cited from the filing evidence.

The filing evidence contains no peer or industry comparison.

Against the prior-year comparative for the six-month year-to-date period, the parent-level result reported for the six-month year-to-date period moved from profit to a loss, with authorized direction decrease, and the operating result on the same longer window shifted from profit to a loss, also with authorized direction decrease. Over the shorter three-month reporting period the parent-level result and the operating result each moved higher than the prior-year comparative for the three-month reporting period, each staying in profit with authorized direction increase and an authorized transition profit to profit, consistent with the description in American Superconductor posts higher year-over-year profit on every reported earnings line for the three-month reporting period as a contrast profile where the quarter improved even though the year-to-date window turned negative.

On the cash side, operating cash generation strengthened over the six-month year-to-date period, with authorized direction increase on Net Cash Provided by (Used in) Operating Activities when set against the prior-year comparative for the six-month year-to-date period, even though the parent-level earnings line moved in the opposite direction over that same longer window. That mismatch is captured in the machine-owned divergence line below. The financing and investing flows over the six-month year-to-date period are likewise covered only by their authorized direction tags and are not narrated further here.

Net Income (Loss) Attributable to Parent was $5,117,000 USD for the six months ended June 30, 2025 and -$643,417,000 USD for the six months ended June 30, 2026, a move that the authorized ledger labels profit to loss with direction decrease. The same line for the three-month reporting period was $5,085,000 USD for the three months ended June 30, 2025 and $78,395,000 USD for the three months ended June 30, 2026, staying in profit on both sides with direction increase. Operating Income (Loss) tracked that same pattern, with $51,013,000 USD for the six months ended June 30, 2025 and -$603,133,000 USD for the six months ended June 30, 2026 (profit to loss, direction decrease), and $29,786,000 USD for the three months ended June 30, 2025 versus $98,465,000 USD for the three months ended June 30, 2026 (profit to profit, direction increase). Net Cash Provided by (Used in) Operating Activities was $13,785,000 USD for the six months ended June 30, 2025 and $42,551,000 USD for the six months ended June 30, 2026, with authorized direction increase.

The pattern resembles the contrast highlighted in Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base, where earnings deteriorate while the company still generates cash; here the earnings deterioration is partial, confined to the six-month window, with the three-month window remaining profitable on both lines.

Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window.

The filing evidence does not attribute this change to any single cause.

Scenario analysis

- Under a continuation case, parent-level earnings for the three-month reporting period print at $78,395,000, a profit that is higher than the prior-year profit of $5,085,000 reported for the three months ended June 30, 2025. The authorized relationship for this line in the catalog is direction increase with a profit-to-profit transition, leaving the six-month window's headline contrast — parent-level net income moving from $5,117,000 (a profit) to -$643,417,000 (a loss) over the half-year year-to-date comparison of the six months ended June 30, 2026 versus the six months ended June 30, 2025 — as the more sensitive swing variable for the next two quarters. A reader tracking BioCryst through the period-ended-2026-06-30 10-Q filing under accession 0001628280-26-053300 would treat that half-year profit-to-loss flip as the floor risk to monitor rather than the quarter's improvement.

- Upside scenarios lean on three signals already disclosed. First, ORLADEYO commercialization is described in the filing as proceeding directly or through partners, with the European ORLADEYO business having been sold to Neopharmed and the related assets and liabilities classified as held for sale on the the three months ended June 30, 2026 balance sheet — a transaction structure that converts European economics into quarterly royalty streams tied to the existing RPI and OMERS Royalty Purchase Agreements. Second, management states that financial resources available at the period-end date will be sufficient to fund operations for at least the next twelve months, a runway statement that constrains near-term dilution pressure even when the half-year parent line moves the other way. Third, the half-year cash flow statements in the authorized comparisons show operating cash generation increasing, financing cash flow moving from a use to a source, and investing cash flow turning from a source to a use — a financing-led shift rather than an earnings-led one. The counter-evidence pattern that pairs stronger operating cash with weaker headline earnings is captured by Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window., which is the framework an upside case has to absorb rather than explain away.

- Downside scenarios concentrate on the half-year loss at -$643,417,000, on the operating loss recorded for the six months ended June 30, 2026 versus the prior-year operating profit at the six months ended June 30, 2025 (a profit-to-loss transition in the authorized catalog), and on the willingness disclosed in the filing to issue common stock, preferred stock, depositary shares, purchase contracts, warrants, debt or units in private placements or registered offerings. Liquidity in a downside case is therefore not gated by the next-twelve-months statement alone; it is gated by access to capital markets and by whether key regulatory and operational developments noted by management go against the company. Where a single driver cannot be isolated from the filing evidence, the appropriate line is The filing evidence does not attribute this change to any single cause.. The filing also contains no peer or industry comparison, so relative-read scenarios should be left as The filing evidence contains no peer or industry comparison. rather than filled in by analogy.

Risks and what to watch

- Reported parent-level net income moved from a profit in the prior-year six-month window to a loss in the current six-month window -$643,417,000 $5,117,000, while the three-month line shifted to a higher profit versus the prior-year quarter $78,395,000 $5,085,000; the divergence between the shorter- and longer-window outcomes is itself the headline risk to track in the next filing. - The filing evidence does not attribute this change to any single cause. - Counter-evidence to the deteriorating six-month earnings line comes from the cash flow narrative.

Operating cash generation strengthened even as reported parent-level earnings moved from profit to a loss over the longer reporting window. - A second counter-evidence lens is the disposition activity referenced in the cited note: the European ORLADEYO business held through the cited subsidiary was reclassified as a disposal group held for sale as of the balance-sheet date and the sale closed in the early part of the fourth fiscal quarter, with an amended intellectual property licence replacing direct ownership Note 7.

Readers should weigh whether the quarter-versus-six-month split reflects the timing of that transaction and the related royalty economics rather than underlying operating momentum The filing evidence does not attribute this change to any single cause.. - Unknowns that the filing evidence does not resolve: - The filing discusses segment reporting as a single reportable and operating segment, leaving no internal line-of-business breakdown to triangulate the parent-level move Note 14. - The financial statements explicitly caution that interim results are not necessarily indicative of full-year outcomes, leaving the run-rate between the second quarter and the remainder of the year unobserved.

- No peer or industry comparison is included in the quoted evidence, so cross-company context must come from outside sources such as Acorn Energy, Inc. Reports Broad Year-Over-Year Decline Across Every Earnings Line Yet Preserves Profitability on a Lower Base. - Metrics to watch next period, framed by what the authorized comparisons already lock in: - Whether the six-month parent-level result returns to a profit or extends the loss, given the current six-month window is a loss versus a prior-year profit -$643,417,000 $5,117,000.

- Whether the three-month parent-level profit builds on or gives back the higher year-over-year print $78,395,000 $5,085,000. - The trajectory of net cash from operating activities, which the authorized comparison frames as having moved higher on a six-month basis. - The trajectory of net cash from financing activities, which the authorized comparison frames as having shifted to a positive six-month figure from a prior-year use.

- Whether investing-activity cash flow continues to register as a six-month use after the prior-period positive base. - The reported risk-factor section in Part II Item 1A and any updated legal proceedings disclosure Item 1 Item 4, since interim risk language can change between filings without a numeric trigger. - Quantitative and qualitative market-risk disclosures Item 3 and any new exhibit or signature items Item 5 Item 6, as those typically accompany a completed divestiture.